International
The Morning Science

What science found today

‹
 

Policy

F.D.A. Rejects Closely Watched Lung Cancer Drug From China

NYT > Health · By Rebecca Robbins ·

F.D.A. Rejects Closely Watched Lung Cancer Drug From China

The Brief

  • The U.S. Food and Drug Administration (FDA) has rejected ivonescimab, a lung cancer drug from China.
  • The New York Times describes the drug as a closely watched symbol of China's rise in drug development.

Why it matters

The decision affects whether this Chinese-developed lung cancer treatment can be marketed in the United States, and it bears on how regulators assess drugs developed largely outside the US.

Who’s affected

  • patients with lung cancer
  • drug developers and regulators

The treatment, called ivonescimab, has become a symbol of China’s rise in drug development.

Timeline

  1. FDA rejects ivonescimab, reported by The New York Times

  2. NYT > Health

    F.D.A. Rejects Closely Watched Lung Cancer Drug From China

How do you feel about this?

0 Comments

    F.D.A. Rejects Closely Watched Lung Cancer Drug From China – The Morning Science